ANNOUNCEMENT: Welcome back. TheLion.com has moved to a new service provider. Please report any issues to email@example.com. Thanks!
|From: QualityStocks (Rep: 4)||Date: 02/20/2013 11:55|
|Forum: QualityStocks - Msg #5717 - List CXM msgs ||Thread #673503424 (Rec: 0) |
|Cardium Therapeutics, Inc. (CXM) and the Generx Strategy|
Cardium Therapeutics’ lead clinical development product candidate is Generx, a DNA-based angiogenic growth factor therapeutic being developed for the potential treatment of patients with advanced coronary artery disease. Unlike other coronary drug therapeutics, Generx is designed to actually stimulate the growth of supplemental collateral blood vessels in the heart in order to enhance myocardial blood flow in patients who have insufficient blood flow due to atherosclerotic plaque restricting flow in the coronary arteries that supply the heart. Generx has progressed through four randomized, placebo-controlled clinical studies at over 100 medical centers in the United States and Western Europe.
Generx is designed as a disease-modifying regenerative medicine therapeutic that can elicit structural and physiologic changes in the heart (the growth of new collateral blood vessels) following a one-time intracoronary administration from a standard cardiac infusion catheter. In contrast, traditional drug therapies such as nitrates and beta blockers provide transient symptomatic relief of anginal chest pain without changing the underlying disease.
It’s ease of use and cost effectiveness make Generx of special potential value in parts of the world where heart disease is increasing, but system availabilities and cost factors make invasive surgical procedures such as coronary angioplasty and stenting, or cardiac bypass surgery, unrealistic. Places like China, India, Russia, as well as Latin America and the Middle East represent vast target markets for Generx. Even in highly industrialized parts of the world, such as the U.S. and Europe, heart disease remains a major problem, and the cost of surgical procedures is putting a growing strain on already over-burdened healthcare systems.
Cardium’s strategy is to move forward with clinical studies for Generx at major medical centers in Russia in connection with commercialization plans covering the marketing and sale of Generx in the Russian Federation. In addition, Cardium will seek clinical development and commercialization partners for Generx in other newly-industrializing countries, such as India, China, and Brazil.
For additional information, visit www.CardiumTHX.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Share This Post:
TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.